Aclaris Therapeutics (ACRS) Cost of Revenue (2017 - 2025)
Historic Cost of Revenue for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $538000.0.
- Aclaris Therapeutics' Cost of Revenue fell 1773.7% to $538000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1948.79%. This contributed to the annual value of $2.8 million for FY2024, which is 1843.41% down from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Cost of Revenue is $538000.0, which was down 1773.7% from $515000.0 recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Cost of Revenue registered a high of $1.3 million during Q2 2021, and its lowest value of $506000.0 during Q1 2025.
- In the last 5 years, Aclaris Therapeutics' Cost of Revenue had a median value of $848000.0 in 2023 and averaged $868947.4.
- Over the last 5 years, Aclaris Therapeutics' Cost of Revenue had its largest YoY gain of 12.38% in 2024, and its largest YoY loss of 4011.52% in 2024.
- Aclaris Therapeutics' Cost of Revenue (Quarter) stood at $1.1 million in 2021, then decreased by 23.67% to $877000.0 in 2022, then fell by 17.33% to $725000.0 in 2023, then dropped by 2.76% to $705000.0 in 2024, then decreased by 23.69% to $538000.0 in 2025.
- Its last three reported values are $538000.0 in Q3 2025, $515000.0 for Q2 2025, and $506000.0 during Q1 2025.